Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VP 20621 for Prevention of Recurrent CDI
NCT01259726Phase 2Completed
- Sponsor
- Takeda
- Start
- Jun 2011
- Primary completion
- Jun 2013
- Modality
- Live Biotherapeutic Products
- Countries
- 6
01
Overview
A Phase 2 trial of nontoxigenic Clostridioides difficile strain M3 in Clostridium difficile infection (CDI), sponsored by Takeda. Started Jun 2011; status: completed.
02
Drugs
nontoxigenic Clostridioides difficile strain M3
03
Conditions
Clostridium difficile infection (CDI)
Beyond the preview
Go deeper on NCT01259726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01259726.